About Novartis
Novartis is a company based in Basel (Switzerland) founded in 1996. The company has 75,880 employees as of December 31, 2024. Novartis has completed 42 acquisitions, including ARCTOS medical, Admune Therapeutics and Advanced Accelerator Applications. Novartis operates in a competitive market with competitors including Catalent, Surrozen, Biotage, Curia and WuXi Biologics, among others.
- Headquarter Basel, Switzerland
- Employees 75880 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novartis Ag
-
Annual Revenue
$48.91 B (USD)8.52as on Dec 31, 2024
-
Net Profit
$11.61 B (USD)-21.2as on Dec 31, 2024
-
EBITDA
$20.9 B (USD)4.58as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
HHS
& 1 more
-
Employee Count
75880
as on Dec 31, 2024
-
Investments & Acquisitions
ARCTOS medical
& 41 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novartis
Novartis is a publicly listed company on the SIX with ticker symbol NOVN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Novartis
Unlock access to complete
Unlock access to complete
Leadership Team
194 people
Software Development Team
81 people
Senior Team
64 people
Sales and Marketing
49 people
Data Analysis and Operations Team
28 people
Human Resources and Administration
22 people
Product Management Team
20 people
Operations Team
19 people
Unlock access to complete
Funding Insights of Novartis
Investors in Novartis
Novartis has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Novartis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novartis
Novartis has strategically engaged in corporate development activities, having acquired 42 companies. Notable acquisitions include ARCTOS medical, Admune Therapeutics and Advanced Accelerator Applications.
Investment portfolio details for Novartis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for kidney diseases are developed by SanReno.
|
Locked | Locked | 2021 | Locked | |
|
Therapeutics for immune disorders are developed by Tourmaline Bio.
|
Locked | Locked | 2021 | Locked | |
|
AAV-based gene therapies for muscle diseases are developed.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Novartis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novartis
Detailed financials for Novartis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novartis Comparisons
Peer comparison for Novartis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novartis
Novartis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Catalent, Surrozen, Biotage, Curia and WuXi Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
CDMO offering drug and biologics development services
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Protein therapeutics are developed and manufactured by WuXi Biologics.
|
Detailed competitors of Novartis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novartis
Complete news archive for Novartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novartis
Novartis was founded in 1996 and raised its 1st funding round 20 years after it was founded.
Novartis is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Vasant Narasimhan is the current CEO of Novartis.
As of Dec 31, 2024, the latest employee count at Novartis is 75,880.
Annual revenue of Novartis is $48.91B as on Dec 31, 2024.
Novartis International AG is a Swiss multinational pharmaceutical company. It ranked number one in sales with 57.9 billion US in the worldwide industry in 2013. In July 2015, Novartis had a market cap of around 280 billion making it the largest healthcare company by this metric. The Company specializes in the research, development, manufacturing, and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care, and generic pharmaceuticals. The Company segments include Pharmaceuticals, which researches, develops, manufactures, distributes, and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines; Alcon, which operates through over three franchises Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, manufactures and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances. In 2022, the company recorded annual revenues of 50.95B and a net profit of 7B.
Yes, Novartis is publicly traded on SIX under the ticker symbol NOVN.
Novartis has made 42 acquisitions, including ARCTOS medical, Admune Therapeutics, and Advanced Accelerator Applications.
Novartis has 2 investors. Key investors include HHS, and European Union.
The ticker symbol of Novartis is NOVN on SIX.